Recombinant Human Chemokine (C-C motif) Ligand 22
|Product Overview :||Recombinant HumanCCL22 is a 8.0 kDa protein containing 67 amino acid residues. Its molecularweight is 8000 Dalton.|
- Gene Information
- Related Products
|Cat. No. :||CCL22-1874H|
|Description :||CCL22 is a proteinthat in humans is encoded by the CCL22 gene. The protein encoded by this geneis secreted by dendritic cells and macrophages, and elicits its effects onits target cells by interacting with cell surface chemokine receptors such asCCR4. The gene for CCL22 is located in human chromosome 16 in a cluster withother chemokines called CX3CL1 and CCL17.|
|Source :||E. coli|
|Molecular Weight :||8.0 kDa|
|Purity :||Greater than 99% bySDS-PAGE and HPLC analyses.|
|Endotoxin Level :||< 0.1 ng/µg ofMDC|
|Biological Activity :||Determined by achemotaxis assay using human T-cells. Significant chemotaxis was achievedusing a concentration of 10.0-100 ng/ml.|
|Reconstitution :||Centrifuge vialprior to opening. The lyophilized MDC is soluble in water and most aqueousbuffers. The lyophilized human MDC can be reconstituted in water to aconcentration of 1.0 mg/ml. This solution can be diluted into other bufferedsolutions or stored frozen at -20°C for future use.|
|Storage :||Thelyophilized protein, though stable at room temperature, is best storeddesiccated below 0°C. Reconstituted MDC should be stored in working aliquotsat -20°C. Avoid repeated freeze-thaw cycles.|
|Gene Name :||CCL22 chemokine (C-C motif) ligand 22 [Homo sapiens ]|
|Synonyms :||CCL22; chemokine(C-C motif) ligand 22; MDC; ABCD-1; SCYA22; STCP-1; DC/B-CK; MGC34554;A-152E5.1; small inducible cytokine A22; CC chemokine STCP-1;macrophage-derived chemokine; stimulated T cell chemotactic protein 1; smallinducible cytokine subfamily A (Cys-Cys), member 22; Macrophage-derivedchemokine; Small-inducible cytokine A22; Stimulated T-cell chemotacticprotein 1; MDC(1-69)|
|Gene ID :||6367|
|mRNA Refseq :||NM_002990|
|Protein Refseq :||NP_002981|
|UniProt ID :||O00626|
|Chromosome Location :||16q13|
|Pathway :||Chemokine receptorsbind chemokines; Chemokine signaling pathway; Cytokine-cytokine receptorinteraction; Class A/1 (Rhodopsin-like receptors); GPCR ligand binding;Peptide ligand-binding receptors; Signal Transduction; Signaling by GPCR|
|Function :||chemokine activity|
|◆ Recombinant Protein|
|CCL22-081C||Active Recombinant Human CCL22 Protein (69 aa)||+Inquiry|
|Ccl22-042C||Active Recombinant Mouse Ccl22 Protein (68 aa)||+Inquiry|
|Ccl22-2034M||Recombinant Mouse Ccl22 Protein, Myc/DDK-tagged||+Inquiry|
|CCL22-2884M||Recombinant Mouse CCL22 Protein||+Inquiry|
|Ccl22-131M||Active Recombinant Mouse Ccl22 Protein||+Inquiry|
|CCL22-7728HCL||Recombinant Human CCL22 293 Cell Lysate||+Inquiry|
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Q&As (6)Ask a question
The expression of CCL22 gene is regulated by a variety of signaling pathways, including inflammatory factor-mediated signaling pathways, cytokine-mediated signaling pathways, and transcription factors.
Studies have shown that by interfering with the interaction of the CCL22 protein and its receptor CCR4, tumor growth, improve inflammatory response, and regulate autoimmune diseases can be inhibited. These findings provide potential application value for the development of corresponding therapeutic strategies.
A number of inhibitors or antagonists that interact with CCL22 proteins have been developed that block the binding of CCL22 to its receptor CCR4, thereby interfering with its biological function.
The mechanism of action of CCL22 protein in specific diseases can be studied through cell culture experiments, animal models, clinical samples, and related biochemical techniques.
There are complex interactions between CCL22 proteins and other chemokines. They may influence the migration and localization of immune cells by competing for receptors, mutual regulation of expression, etc.
Some studies have shown that in tumor immunotherapy, inhibiting the expression of CCL22 or interfering with its interaction with CCR4 can enhance the effect of immunotherapy and improve the survival rate of patients.
Customer Reviews (0)Write a review
Ask a Question for All CCL22 Products
Required fields are marked with *
My Review for All CCL22 Products
Required fields are marked with *